Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

otocol Assessment (SPA) agreement with the FDA, the Phase 3 clinical program for Zerenex consists of two clinical studies, the completed short-term study, and a long-term safety and efficacy study that is currently ongoing.

About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that in
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced the results ... "This was a transformational year in Relmada,s ... future for our company," said Sergio Traversa , ... we have executed on key financial, human resource and ...
(Date:12/17/2014)... Achim Noack has been named global vice president ... position, Noack will assist Jerry Stoller, CEO and president ... and supervise global marketing management and implementation of new ... and experience in the crop protection industry,” says Jerry ... thinking will be a great asset for Stoller Group, ...
(Date:12/17/2014)... December 17, 2014 Xeno Diagnostics ... following its most recent COLA inspection. Xeno has ... a national healthcare accreditation organization. Accreditation is earned ... quality in day-to-day operations, demonstrate continued accuracy in ... rigorous on-site laboratory survey. , While ...
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... April 11, 2012 UBM Canon,s Medical Design ... for medical device design and innovation, has announced that ... Achievement Award to Dr. Thomas Fogarty during the ... (Photo: http://photos.prnewswire.com/prnh/20120411/LA84898 ) (Logo: ...
... CAYMAN, Cayman Islands, April 10, 2012 Narayana ... partnership with Ascension Health Alliance of the United ... Cayman Islands. Narayana Hrudayalaya Hospitals (NH) ... Devi Prasad Shetty, a world-renowned cardiovascular surgeon with ...
... MILFORD, Mass., April 10, 2012  Psyche Systems Corporation ... Healthcare, Malvern, Pa., under which WindoPath®, Psyche,s award ... the anatomic pathology component of NOVIUS® Lab, Siemens ... provides an enterprise-wide workflow solution that is built ...
Cached Biology Technology:UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award 2UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award 3Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman 2Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman 3Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman 4Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions 2
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... AMSTERDAM , April 27, 2010 ... in heightened focus on credit risk,management throughout Europe ... marginal improvement in payment behaviour of domestic,and foreign buyers ... may,reflect the response to tighter, more diligent credit management ...
... LONDON , April 27, 2010 Dominio ... partner for the .CO domain name launch. , ... Julio Camacho , CEO, Dominio Amigo ... years they have consistently performed,at both ccTLD and gTLD launches, securing the very ...
... JINZHOU CITY, China , April 27 /PRNewswire-Asia/ -- Wonder ... supplier of,automotive electric parts, suspension products and engine components in China ,wins ... of,its subsidiaries, which is Jinzhou Wanyou Mechanical Parts Co., Ltd ("Wanyou"). , ... On 23 April, Wanyou ...
Cached Biology News:Payment Default Risks Remain a Crucial Issue for Businesses Across Europe 2Payment Default Risks Remain a Crucial Issue for Businesses Across Europe 3Payment Default Risks Remain a Crucial Issue for Businesses Across Europe 4Dominio Amigo Announce Domainmonster as .CO Technical Partner 2Dominio Amigo Announce Domainmonster as .CO Technical Partner 3Wonder Auto Obtains a New World-class Customer in Germany 2Wonder Auto Obtains a New World-class Customer in Germany 3
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human GFR alpha-4 Affinity Purified Polyclonal Ab...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Human Siglec-9 Biotinylated Affinity Purified Pab...
Biology Products: